With One and a Half Million People Dying from TB Every Year, It’s Time to Accelerate Progress
The public health progress in the World Health Organization’s Global Tuberculosis (TB) Report 2019 this year can be found in
Press Releases
TB Alliance Statement on TB REACH Wave 7
TB Alliance applauds the Stop TB Partnership’s TB REACH program for investing in efforts to combat tuberculosis (TB). The $15.4
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S.
TB Community Urges Global Leaders to “Walk the Talk” on Investing in TB Research
On July 28th in South Africa, more than 100 members of the TB research community marched under the Louder than
Statement on TB and HIV Coinfection Ahead of IAS2019
July 18, 2019—Tuberculosis (TB) is the leading infectious cause of death worldwide and the number one cause of death among
TB Alliance Names Eugene Sun as Senior Vice President for Research and Development
NEW YORK (June 25, 2019)—TB Alliance today announced the appointment of Eugene Sun, MD to the position of Senior Vice
Health 20 Annual Summit will urge G20 Health and Finance Ministers to enforce the necessary marriage between the wealth and the health of nations
The G20’s top health and health financing experts will assemble in Tokyo on the eve of the Osaka G20 heads
New Milestone for Children with Tuberculosis Reached as One Million Treatments of Child-Friendly Medicines are Ordered
SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered
Mitchell Warren Elected President of TB Alliance Stakeholders Association, Joins Board of Directors
NEW YORK (June 12, 2019)—TB Alliance, a not-for-profit organization leading the development of new, improved and affordable tuberculosis (TB) treatments,
FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis
Investigational drug pretomanid, developed by non-profit TB Alliance, is under regulatory review for treatment of extensively drug-resistant tuberculosis and treatment-intolerant